🇺🇸 FDA
Pipeline program

16 mg buprenorphine with 4 mg naloxone sublingual film

71936002

Approved other terminated

Quick answer

16 mg buprenorphine with 4 mg naloxone sublingual film for Evaluation of QTc Interval is a Approved program (other) at TEVA PHARMACEUTICAL INDUSTRIES LTD with 1 ClinicalTrials.gov record(s).

Program details

Company
TEVA PHARMACEUTICAL INDUSTRIES LTD
Indication
Evaluation of QTc Interval
Phase
Approved
Modality
other
Status
terminated

Clinical trials